Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986]

Affiliations

• ¹ Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: [email protected].
• ² Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
• ³ Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
• ⁴ Center for Hematology and Oncology Bethanien, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany.
• ⁵ Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, UK.
• ⁶ International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
• ⁷ Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg, Marburg, Germany.
• ⁸ Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.
• ⁹ Department of Surgery, University Hospital Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.
• ¹⁰ SwissBreastCare, Bethanienspital, Zürich, Switzerland; SONK Foundation, St. Gallen, Switzerland.